11
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T16807 | Rucaparib monocamsylate | Rucaparib Camsylate | PARP |
Rucaparib monocamsylate (Rucaparib Camsylate) is a PARP inhibitor (PARP1,Ki of 1.4 nM). Rucaparib Camsylate also displays binding affinity to eight other PARP domains. | |||
T4463 | Rucaparib | AG-14447,PF-01367338,AG014699 | PARP |
Rucaparib (PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP. | |||
T6127 | Rucaparib Phosphate | AG-014699 phosphate,PF-01367338,AG-014699,PF-01367338 phosphate | PARP |
Rucaparib Phosphate (PF-01367338 phosphate) is an inhibitor of PARP (Ki: 1.4 nM for PARP1) that is used in clinical therapy to sensitize cancer cells to chemotherapy. | |||
T8440 | LASSBio-1135 | TNF , TRP/TRPV Channel | |
LASSBio-1135 is an orally effective antagonist of TRPV1 and inhibitor of TNF-α production. | |||
T24389 | LASSBio-1366 | LASSBio 1366 | |
LASSBio-1366 is an agonist of adenosine A2a receptor that acts by attenuating the progression of monocrotaline-induced pulmonary hypertension. | |||
T32582 | LASSBio-881 | LASSBio881,LASSBio 881 | |
LASSBio-881 is a non-selective partial agonist of the CB1 and CB2 cannabinoid receptors, as well as an antagonist of the TRPV1 receptor. | |||
T70164 | LASSBio-1829 HCl | ||
LASSBio-1829 HCl is an orally active IKK2 inhibitor. | |||
T61794 | LASSBio-1632 | ||
LASSBio-1632 is a novel anti-asthmatic lead candidate that selectively inhibits PDE4A and PDE4D isoenzymes, leading to the suppression of airway hyper-reactivity (AHR) and TNF-α production in lung tissue. With high exper... | |||
T24388 | LASSBio-1359 | LASSBio1359,LASSBio 1359 | |
LASSBio-1359 is an adenosine receptor agonist. It acts by inducing relaxation of the corpus cavernosum. It also acts as a novel selective phosphodiesterase. | |||
T9430 | Venadaparib | NOV140101,IDX-1197 | PARP |
Venadaparib (NOV140101) (IDX-1197) is a potent, selective and orally active PARP inhibitor with IC50s of 1.4 nM and 1.0 nM for PARP1 and PARP2, respectively. Venadaparib is insensitive to PARP-5. Venadaparib prevents the... | |||
T9756 | AZD-9574 | PARP | |
AZD-9574 is a selective inhibitor of PARP1 at the sites of SSBs. AZD-9574 exhibits anti-cancer activities and can be used in studies about HRD+ breast cancer and advanced solid malignancies. |